Key result
Telmisartan is an angiotensin II receptor blocker with antihypertensive, metabolic, and vascular effects that has been evaluated in large-scale cardiovascular morbidity and mortality trials.
Why the study?
Does telmisartan reduce cardiovascular morbidity and mortality in subjects at high vascular risk?
Does telmisartan reduce cardiovascular morbidity and mortality in subjects at high vascular risk?
Telmisartan is an ARB with antihypertensive, metabolic, and vascular protective effects that has been extensively studied in high cardiovascular risk populations.
Answers are grounded in this paper and cite their sources.
Telmisartan may aid vascular risk modification; leaves open confirmation in prospective outcome trials.
Impact of telmisartan in modifying vascular risk Jean-Philippe Baguet, Olivier Ormezzano, Gilles Barone-RochetteClinique de Cardiologie, Centre Hospitalier Universitaire de Grenoble, Grenoble, FranceAbstract: Telmisartan, a selective angiotensin II type 1 receptor blocker (ARB), has been investigated in many trials, in particular, in order to assess its antihypertensive effect in various situations and its ability to protect organs susceptible to hypertension. In addition to its antihypertensive properties, it has positive metabolic and vascular effects (partly because of its sustained action). Several large-scale trials have focused on the effect of telmisartan on cardiovascular morbidity and mortality, including comparisons of that with an angiotens-inconverting enzyme inhibitor in subjects at high vascular risk. Telmisartan was used in the largest ARB research programme (the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial [ONTARGET] and Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease [TRANSCEND] trial).
No takes yet. Share an insight, caveat, or question.
Jean-Philippe Baguet (2010) conducted a review in Hypertension and cardiovascular risk. Telmisartan was evaluated. Telmisartan is an angiotensin II receptor blocker with antihypertensive, metabolic, and vascular effects that has been evaluated in large-scale cardiovascular morbidity and mortality trials.
Synapse has enriched 10 related papers. Consider them for comparative context: